Published in Paediatr Drugs on January 01, 2003
Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry (2006) 2.49
Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgmont) (2009) 1.55
Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed (2006) 1.51
Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health (2008) 1.37
The neurobiological basis of ADHD. Ital J Pediatr (2010) 0.99
The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat (2011) 0.82
Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med (2008) 0.81
Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry (2008) 0.79
Drug therapy of attention deficit hyperactivity disorder: current trends. Mens Sana Monogr (2012) 0.78
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. Mol Neurobiol (2016) 0.76
Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions. Atten Defic Hyperact Disord (2014) 0.76
Changes in behavior as side effects in methylphenidate treatment: review of the literature. Neuropsychiatr Dis Treat (2016) 0.75
Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD. Prim Care Companion J Clin Psychiatry (2010) 0.75
Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry (2017) 0.75
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 11.25
Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 10.19
Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry (2006) 10.00
Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry (2006) 9.98
Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 9.85
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Previously suicidal adolescents: predictors of six-month outcome. J Can Acad Child Adolesc Psychiatry (2008) 2.98
The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. J Am Acad Child Adolesc Psychiatry (2013) 2.48
A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol (2006) 2.08
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2006) 1.95
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Assessment and management of sleep problems in youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2013) 1.67
Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry (2003) 1.53
Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol (2011) 1.37
Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry (2003) 1.29
The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci (2009) 1.15
Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry (2002) 1.13
Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord (2003) 1.08
Inattention, working memory, and academic achievement in adolescents referred for attention deficit/hyperactivity disorder (ADHD). Child Neuropsychol (2011) 1.07
Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry (2003) 1.06
Psychiatric human resources planning in Canada. Position paper. Canadian Psychiatric Association. Can J Psychiatry (2010) 1.05
Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry (2007) 1.04
Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder. Eur Child Adolesc Psychiatry (2006) 1.01
A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry (2003) 0.98
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry (2012) 0.95
ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics (2012) 0.95
Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2004) 0.93
Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2007) 0.91
Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. J Child Adolesc Psychopharmacol (2014) 0.90
Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. Clin Drug Investig (2014) 0.88
Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. J Child Adolesc Psychopharmacol (2010) 0.87
Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep (2007) 0.86
Future research directions in sleep and ADHD: report of a consensus working group. J Atten Disord (2012) 0.85
Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis. Eur Child Adolesc Psychiatry (2008) 0.85
Perceptions of girls and ADHD: results from a national survey. MedGenMed (2004) 0.83
The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. CNS Spectr (2007) 0.82
Children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment: impact on parental practices. J Am Acad Child Adolesc Psychiatry (2004) 0.81
HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin (2009) 0.81
Prospective clinical evaluation of 1440-nm laser delivered by microarray for treatment of photoaging and scars. J Drugs Dermatol (2006) 0.81
Maintenance study for adolescent depression. J Child Adolesc Psychopharmacol (2008) 0.80
Operator independent focused high frequency ISM band for fat reduction: porcine model. Lasers Surg Med (2013) 0.78
Treatment of catatonia with electroconvulsive therapy in adolescents. J Child Adolesc Psychopharmacol (2012) 0.78
Pharmacological management of a youth with ADHD and a seizure disorder. J Am Acad Child Adolesc Psychiatry (2006) 0.77
Comments on "Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials" by Muller and associates. J Clin Psychopharmacol (2003) 0.75
Re: Motivation and mechanism in motor vehicle collisions. Can J Psychiatry (2006) 0.75
When patients do not have a proxy: a procedure for medical decision making when there is no one to speak for the patient. J Clin Ethics (2006) 0.75
Two-treatment protocol for skin laxity using 90-Watt dynamic monopolar radiofrequency device with real-time impedance intelligence monitoring. J Drugs Dermatol (2014) 0.75
The effects of instructions on mothers' ratings of child attention-deficit/hyperactivity disorder symptoms. J Abnorm Child Psychol (2011) 0.75
Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. J Clin Pharmacol (2004) 0.75